Group 1 - The core viewpoint of the article is that Wei Jun Biotechnology (00660.HK) reported significant revenue growth and a reduction in losses for the six months ending December 31, 2025, compared to the same period in the previous year [1] Group 2 - For the six months ending December 31, 2025, the company recorded revenue of approximately HKD 352 million, an increase of 118.7% from approximately HKD 161 million for the six months ending December 31, 2024 [1] - The loss attributable to the owners of the company for the six months ending December 31, 2025, was approximately HKD 5.9 million, a decrease from a loss of approximately HKD 13.7 million for the same period in 2024 [1] - The reduction in losses was primarily due to the increase in revenue and a decrease in financial costs during the reporting period [1]
玮俊生物科技(00660.HK)中期净亏损为590万港元 同比收窄约57.0%